Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATMOS: Inhaled Mosliciguat in PAH and CTEPH
NCT03754660Phase 1Completed
- Sponsor
- Bayer
- Start
- Jan 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of mosliciguat in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) (3 arms), sponsored by Bayer. Primary endpoints: Peak percent reduction in Pulmonary Vascular Resistance (PVR) from baseline 2 and Peak percent reduction in Pulmonary Vascular Resistance (PVR) from baseline. Started Jan 2019; status: completed.
02
Drugs
mosliciguat
03
Conditions
pulmonary arterial hypertension (PAH)chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT03754660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03754660.